Bexion Pharmaceuticals was named the Biotech Innovation Award winner at the Cincinnati USA Innovation Awards program sponsored by the Cincinnati Business Courier, the Cincinnati USA Regional Chamber and CincyTech. The Innovation Awards celebrate outstanding innovation and the companies and people who have shown how new ideas can be developed into fuel for the regional Tri-State (Ohio/Kentucky/Indiana) economic engine.
"The Bexion team is honored to be the very first winner of the Biotech Innovation Award," stated Dr. Ray Takigiku, co-founder and CEO of Bexion. "Cancer treatment and diagnosis is in dire need of innovation. We believe, and the award judges appear to agree, that our approach represents an entirely new, exciting and potentially paradigm-shifting approach to the treatment of cancer."
Bexion is developing BXQ-350 nanovesicles as a potential treatment for the form of brain cancer called glioblastoma. BXQ-350 nanovesicles have an affinity for the membrane patches that are common in many types of tumor cells including glioblastoma cells. Bexion's studies have shown effectiveness in the laboratory in multiple animal tumor models, and across a remarkable range of tumors in the test tube.
Study shows AI can predict prognosis in triple-negative breast cancer